Standard
The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa. / Ring, Hans Christian; Thomsen, Simon F.
I:
British Journal of Dermatology, Bind 187, Nr. 2, 2022, s. 274-274.
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Harvard
Ring, HC
& Thomsen, SF 2022, '
The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa',
British Journal of Dermatology, bind 187, nr. 2, s. 274-274.
https://doi.org/10.1111/bjd.21045APA
Ring, H. C.
, & Thomsen, S. F. (2022).
The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa.
British Journal of Dermatology,
187(2), 274-274.
https://doi.org/10.1111/bjd.21045Vancouver
Ring HC
, Thomsen SF.
The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa.
British Journal of Dermatology. 2022;187(2):274-274.
https://doi.org/10.1111/bjd.21045Author
Ring, Hans Christian ; Thomsen, Simon F. / The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa. I: British Journal of Dermatology. 2022 ; Bind 187, Nr. 2. s. 274-274.
Bibtex
@article{9bc2558511af4f2b8ecc850b1abbeda3,
title = "The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa",
author = "Ring, {Hans Christian} and Thomsen, {Simon F.}",
note = "Conflicts of interest: H.C.R. has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from LEO Pharma. S.F.T. has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB.",
year = "2022",
doi = "10.1111/bjd.21045",
language = "English",
volume = "187",
pages = "274--274",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "2",
}
RIS
TY - JOUR
T1 - The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa
AU - Ring, Hans Christian
AU - Thomsen, Simon F.
N1 - Conflicts of interest: H.C.R. has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from LEO Pharma. S.F.T. has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB.
PY - 2022
Y1 - 2022
U2 - 10.1111/bjd.21045
DO - 10.1111/bjd.21045
M3 - Letter
C2 - 35122235
AN - SCOPUS:85129563325
VL - 187
SP - 274
EP - 274
JO - British Journal of Dermatology
JF - British Journal of Dermatology
SN - 0007-0963
IS - 2
ER -
